<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04300621</url>
  </required_header>
  <id_info>
    <org_study_id>CR108774</org_study_id>
    <secondary_id>2019-004428-39</secondary_id>
    <secondary_id>54135419EDI1003</secondary_id>
    <nct_id>NCT04300621</nct_id>
  </id_info>
  <brief_title>A Study of Different Oral Thin Film (S)-Ketamine Formulations for Sublingual Administration in Healthy Participants</brief_title>
  <official_title>An Open-label, Randomized, Four-way Crossover, Single Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Different Oral Thin Film (S)-Ketamine Formulations for Sublingual Administration in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study in healthy participants is to characterize the plasma&#xD;
      pharmacokinetic (PK) profile of different single dose Oral Thin Film (OTF) (S)-ketamine&#xD;
      formulations administered sublingually.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 19, 2020</start_date>
  <completion_date type="Actual">August 10, 2020</completion_date>
  <primary_completion_date type="Actual">August 10, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Maximum plasma concentration will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve from Time 0 To Time Of the Last Quantifiable Concentrations [AUC(0-last)]</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to time of the last quantifiable concentrations will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve from Time 0 to Infinite Time [AUC(0-infinity)]</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to infinite time, calculated as the sum of AUC(last) and C(last)/lambda, in which C(last) is the last observed quantifiable concentrations will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Abnormalities in Vital sign (Systolic Blood Pressure [SBP] and Diastolic Blood Pressure [DBP])</measure>
    <time_frame>Day 1</time_frame>
    <description>Number of participants with clinically significant abnormalities in blood pressure (Systolic Blood Pressure [SBP], Diastolic Blood Pressure [DBP]) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Abnormalities in Vital Sign (Heart Rate)</measure>
    <time_frame>Day 1</time_frame>
    <description>Number of participants with clinically significant abnormalities in vital sign (heart rate) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Abnormalities in Electrocardiogram (ECGs)</measure>
    <time_frame>Day 1 and 2</time_frame>
    <description>Number of participants with clinically significant abnormalities in ECG will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Abnormalities in Laboratory Parameters</measure>
    <time_frame>Day 1 and 2</time_frame>
    <description>Number of participants with clinically significant abnormalities in laboratory parameters (Hematology, Clinical chemistry and routine analysis) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events and Serious Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to Day 7</time_frame>
    <description>An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment Sequence 1: OTF 1, 4, 2, 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of (S)-ketamine administered sublingually through OTF 1 in period 1; followed by OTF 4 in period 2; followed by OTF 2 in period 3; followed by OTF 3 in period 4, on Day 1 of each treatment period under fasted conditions. A washout period of at least 72 hours will be maintained between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 2: OTF 2, 1, 3, 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of (S)-ketamine administered sublingually through OTF 2 in period 1; followed by OTF 1 in period 2; followed by OTF 3 in period 3; followed by OTF 4 in period 4, on Day 1 of each treatment period under fasted conditions. A washout period of at least 72 hours will be maintained between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 3: OTF 3, 2, 4, 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of (S)-ketamine administered sublingually through OTF 3 in period 1; followed by OTF 2 in period 2; followed by OTF 4 in period 3; followed by OTF 1 in period 4, on Day 1 of each treatment period under fasted conditions. A washout period of at least 72 hours will be maintained between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 4: OTF 4, 3, 1, 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of (S)-ketamine administered sublingually through OTF 4 in period 1; followed by OTF 3 in period 2; followed by OTF 1 in period 3; followed by OTF 2 in period 4, on Day 1 of each treatment period under fasted conditions. A washout period of at least 72 hours will be maintained between each treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTF 1</intervention_name>
    <description>Participants will receive (S)-ketamine administered sublingually through OTF 1.</description>
    <arm_group_label>Treatment Sequence 1: OTF 1, 4, 2, 3</arm_group_label>
    <arm_group_label>Treatment Sequence 2: OTF 2, 1, 3, 4</arm_group_label>
    <arm_group_label>Treatment Sequence 3: OTF 3, 2, 4, 1</arm_group_label>
    <arm_group_label>Treatment Sequence 4: OTF 4, 3, 1, 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTF 2</intervention_name>
    <description>Participants will receive (S)-ketamine administered sublingually through OTF 2.</description>
    <arm_group_label>Treatment Sequence 1: OTF 1, 4, 2, 3</arm_group_label>
    <arm_group_label>Treatment Sequence 2: OTF 2, 1, 3, 4</arm_group_label>
    <arm_group_label>Treatment Sequence 3: OTF 3, 2, 4, 1</arm_group_label>
    <arm_group_label>Treatment Sequence 4: OTF 4, 3, 1, 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTF 3</intervention_name>
    <description>Participants will receive (S)-ketamine administered sublingually through OTF 3.</description>
    <arm_group_label>Treatment Sequence 1: OTF 1, 4, 2, 3</arm_group_label>
    <arm_group_label>Treatment Sequence 2: OTF 2, 1, 3, 4</arm_group_label>
    <arm_group_label>Treatment Sequence 3: OTF 3, 2, 4, 1</arm_group_label>
    <arm_group_label>Treatment Sequence 4: OTF 4, 3, 1, 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTF 4</intervention_name>
    <description>Participants will receive (S)-ketamine administered sublingually through OTF 4.</description>
    <arm_group_label>Treatment Sequence 1: OTF 1, 4, 2, 3</arm_group_label>
    <arm_group_label>Treatment Sequence 2: OTF 2, 1, 3, 4</arm_group_label>
    <arm_group_label>Treatment Sequence 3: OTF 3, 2, 4, 1</arm_group_label>
    <arm_group_label>Treatment Sequence 4: OTF 4, 3, 1, 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body Mass Index (BMI) between 20.0 and 28.0 kilogram per square meters (kg/m^2)&#xD;
             inclusive (BMI=weight/height^2) with a minimum weight of 60 kilogram (kg) and a&#xD;
             maximum of 100 kg&#xD;
&#xD;
          -  Participant must be healthy based on clinical laboratory tests performed at screening.&#xD;
             If the results of the serum chemistry panel, hematology or urinalysis are outside the&#xD;
             normal reference ranges, retesting of an abnormal lab value(s) that may lead to&#xD;
             exclusion will be allowed once during the screening phase&#xD;
&#xD;
          -  Nonsmoker (not smoked for 3 months prior to screening)&#xD;
&#xD;
          -  A woman must have a negative serum beta-human chorionic gonadotropin (beta-hCG) at&#xD;
             screening and a negative urine pregnancy test on Day -1 of each Period&#xD;
&#xD;
          -  A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted&#xD;
             reproduction during the study and for at least 1 month after the last study&#xD;
             intervention administration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiac arrhythmias or other cardiac disease, hematological disease, hypertension,&#xD;
             lipid abnormalities, respiratory disease, diabetes mellitus, renal or hepatic&#xD;
             insufficiency, thyroid disease, Parkinson's disease, infection, glaucoma, epilepsy or&#xD;
             any other illness that the Investigator considers should exclude the participant&#xD;
&#xD;
          -  Positive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies&#xD;
             or human immunodeficiency virus (HIV) antibodies at screening visit&#xD;
&#xD;
          -  Drinks, on average, more than 5 cups of tea/coffee/cocoa or 8 cans of cola per day&#xD;
&#xD;
          -  Clinically significant acute illness within 7 days prior to each study intervention&#xD;
             administration&#xD;
&#xD;
          -  History of clinically significant drug and/or food allergies including known&#xD;
             allergies, hypersensitivity, or intolerance to JNJ-54135419 or its excipients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SGS Life Science Services</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2020</study_first_posted>
  <last_update_submitted>September 10, 2020</last_update_submitted>
  <last_update_submitted_qc>September 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency.&#xD;
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

